Ustekinumab is a humanized monoclonal antibody belonging to the IL-12/IL-23 inhibitor class, utilized for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and… Read more
Ustekinumab is a humanized monoclonal antibody belonging to the IL-12/IL-23 inhibitor class, utilized for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. By specifically blocking the p40 subunit shared by interleukin-12 and interleukin-23, this therapeutic agent modulates inflammatory immune responses. To support the rigorous analytical requirements of pharmaceutical development, this category offers essential reference standards, including pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds. These high-quality materials are critical for laboratories performing impurity profiling, method validation, and quantitative analysis during the quality control of drug substances and finished products. By utilizing these precise analytical tools, researchers can ensure compliance with regulatory standards and maintain consistent product integrity throughout the drug manufacturing lifecycle.